Welcome to Avandia® News. This website intends to provide timely information about Avandia® and will provide users with the latest information regarding the recent Avandia® warning issued by the U.S. Food and Drug Administration (FDA). 

Recent Update: FDA to Keep Avandia® on U.S. Market
Despite evidence of life-threatening health risks, the U.S. Food and Drug Administration (FDA) announced, Sept. 23, 2010, that it will allow Avandia® to stay on the market. The decision has sparked controversy, as the diabetes drug has been linked to heart risks including heart attack and stroke.

The FDA says it plans to tighten restrictions on the drug, and will only allow patients who cannot control their diabetes with other medications to use it. Avandia® (rosiglitazone) is used for the treatment of type 2 diabetes. The FDA began questioning whether to keep the drug on the market when a link to heart risks was confirmed.

Actos®, a drug in the same class, has been proven safer than Avandia®. However, the FDA has decided to keep Avandia® on the market. Some ask why. According to reports, patients taking Avandia® have a 15 percent higher chance of death and a 13 percent higher chance of suffering congestive heart failure than those taking Actos®.

Members of the FDA who voted to keep Avandia® on the market argue that the evidence of heart risks is not consistent. They also note some patients may benefit from the drug.

Avandia® has been banned in Europe.

Potential Dangers Associated with Avandia®
According to reports, Avandia® has been linked to serious, life-threatening conditions, including congestive heart failure, heart attack, stroke and liver failure. Patients who suffer these conditions may be at risk of death.

If your or someone you love has a suffered a severe injury while taking Avandia®, you may be eligible to recover compensation for your pain and suffering. For more information, consult with an experienced lawyer for defective drugs.